Drug Safety

, Volume 21, Supplement 1, pp 33–38 | Cite as

Cardiotoxicity of Histamine and the Possible Role of Histamine in the Arrhythmogenesis Produced by Certain Antihistamines

  • Jesús Llenas
  • Ignasi Cardelús
  • Ascensión Heredia
  • Fernando de Mora
  • Robert W. Gristwood
Review Article

Abstract

Since 1990 it has repeatedly been reported that some histamine H1 receptor antagonists (e.g. terfenadine and astemizole) are able to produce ventricular arrhythmias (e.g. torsade de pointes) when they are given at dosages above the therapeutic range and/or administered together with cytochrome P-450 3A4 inhibitors, such as ketoconazole or erythromycin. Although the mechanism by which these arrhythmias are produced remains unclear, the recently reported ability of these drugs to block outward K+ currents has been suggested as the cause of their arrhythmogenic effects. Alternatively, we have observed that some H1 antihistamines, including terfenadine and astemizole, are able to release histamine from guinea-pig cardiac mast cells. Thus, we have proposed that the liberated histamine, acting through an H2 receptor-stimulating mechanism, can prolong the action potential duration and hence induce arrhythmogenic effects. This paper describes experimental observations supporting the hypothesis that some H1 antihistamines can induce severe cardiac arrhythmias via the local release of histamine.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dale H, Laidlaw P. Histamine shock. J Physiol (Lond) 1919; 52: 355–90Google Scholar
  2. 2.
    Wolff A, Levi R. Histamine and cardiac arrhythmias. Circ Res 1986; 58: 1–16PubMedCrossRefGoogle Scholar
  3. 3.
    Levi R, Rubin L, Gross S. Histamine in cardiovascular function and dysfunction: recent developments. In: Uvinas B, editor. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1991; 97: 347–84Google Scholar
  4. 4.
    Gristwood R, Owen D, Smith I. Inhibition by cimetidine of cardiac stimulation due to mast cell degranulation. Br J Pharmacol 1980; 70: 105–6Google Scholar
  5. 5.
    Heredia A, Beleta J, Llenas J, et al. Terfenadine and the main metabolite of loratadine release histamine from cardiac mast cells: possible cardiotoxic consequences. Ann Allergy Asthma Immunol 1997; 78: 142Google Scholar
  6. 6.
    Tobin J, Doyle T, Ackerman A, et al. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991; 266: 2737–40PubMedCrossRefGoogle Scholar
  7. 7.
    Cardelús I, Llenas J, Gristwood R, et al. Terfenadine increases the force of contraction of guinea pig ventricular strips by a histamine H2-dependent mechanism. Br J Pharmacol 1995; 114: 258PGoogle Scholar
  8. 8.
    Eckel L, Gristwood R, Nawrath H, et al. Inotropic and electrophysiological effects of histamine on human ventricular heart muscle. J Physiol 1982; 330: 111–23PubMedGoogle Scholar
  9. 9.
    Gristwood R, Lincoln J, Owen D, et al. Histamine release from human right atrium. Br J Pharmacol 1981; 74: 7–9PubMedCrossRefGoogle Scholar
  10. 10.
    Levi R, Malm J, Bouman F, et al. The arrhythmogenic actions of histamine on human atrial fibres. Circ Res 1981; 49: 545–50PubMedCrossRefGoogle Scholar
  11. 11.
    Caron J, Adamantidis M, Bordet R, et al. Effets proarythmiques des antihistaminiques H1. Lett Pharmacol 1996; 10: 200–7Google Scholar
  12. 12.
    Levi R, Hordof A, Edie R, et al. Histamine effect on human atria. Circulation 1978; 58: 105Google Scholar
  13. 13.
    Ginsburg R, Bristow M, Stinson E, et al. Histamine receptors in the human heart. Life Sci 1980; 26: 2245–9PubMedCrossRefGoogle Scholar
  14. 14.
    Ginsburg R, Erikson M, Bristow M, et al. Histamine receptors in rabbit, pig and human myocardium. Clin Res 1980; 28: 6AGoogle Scholar
  15. 15.
    Owen D. Histamine receptors in the cardiovascular system. Gen Pharmacol 1977; 8: 141–56PubMedCrossRefGoogle Scholar
  16. 16.
    Flynn B, Gristwood RW, Owen DA. Histamine-induced increases in cardiac work in vitro. Agents Actions 1978; 8:388PubMedCrossRefGoogle Scholar
  17. 17.
    Borchard U, Hafner D, Hirth C. Electrophysiological actions of histamine and H1-, H2-receptor antagonists in cardiac tissue. Agents Actions 1986; 18: 186–90PubMedCrossRefGoogle Scholar
  18. 18.
    Giotti A, Guidotti A, Mannaioni P, et al. The influences of adrenotropic drugs and noradrenaline on the histamine release in cardiac anaphylaxis in vitro. J Physiol 1966; 184: 924–41PubMedGoogle Scholar
  19. 19.
    Patella V, Marinò I, Lampärter B, et al. Human heart mast cells. Isolation, purification, ultrastructure and immunologic characterization. J Immunol 1995; 154: 2855–65PubMedGoogle Scholar
  20. 20.
    Feigen G, Vaughan Williams E, Peterson J, et al. Histamine release and intracellular potentials during anaphylaxis in the isolated heart. Circulation Res 1960; 8: 713–23PubMedCrossRefGoogle Scholar
  21. 21.
    Feigen G, Prager D. Experimental cardiac anaphylaxis. Physiologic, pharmacologic and biochemical aspects of immune reactions in the isolated heart. Am J Cardiol 1969; 24: 474–91PubMedCrossRefGoogle Scholar
  22. 22.
    Capurro N, Levi R. Immunologic release of histamine from the heart: inhibition by dibutyryl cyclic AMP. Fedn Proc 1971; 30: 499Google Scholar
  23. 23.
    Capurro N, Levi R. Anaphylaxis in the guinea pig isolated heart: selective inhibition by burimamide of the positive inotropic and chronotropic effects of released histamine. Br J Pharmacol 1973; 48: 620–8PubMedCrossRefGoogle Scholar
  24. 24.
    Levi R. Effects of exogenous and immunologically released histamine on the isolated heart: a quantitative comparison. J Pharmacol Exp Ther 1972; 182: 227–38PubMedGoogle Scholar
  25. 25.
    Pellerat J, Murat M. Action des antihistaminiques de synthèse sur l’histaminémie. C R Soc Biol Paris 1946; 140: 297Google Scholar
  26. 26.
    Arunlakshana O. Histamine release by antihistamines. J Physiol 1952; 119:47Google Scholar
  27. 27.
    Patella V, de Crescenzo G, Lamparter-Schummert B, et al. Increased cardiac mast cell density and mediator release in patients with dilated cardiomyopathy. Inflamm Res 1997 Mar;46 Suppl. 1: S31–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Jesús Llenas
    • 1
  • Ignasi Cardelús
    • 1
  • Ascensión Heredia
    • 1
  • Fernando de Mora
    • 2
  • Robert W. Gristwood
    • 3
  1. 1.Department of Pharmacological Development, Research CentreAlmirall Prodesfarma S.A.BarcelonaSpain
  2. 2.Department of Pharmacology, Facultad de VeterinariaUniv. Autónoma de BarcelonaBarcelonaSpain
  3. 3.Stevenage Biosciences LtdStevenage, HertfordshireEngland

Personalised recommendations